HIGHLIGHTS
- who: Yanhua Chen from the the emergence of second-generation AR antagonists, which began with the approval of enzalutamide in , by the United States have published the article: Second generation androgen receptor antagonists and challenges in prostate cancer treatment, in the Journal: (JOURNAL) of 27/01/1989
- what: In reviewing the mechanisms of AR antagonist resistance, changes in the AR signaling pathway stand out as one of the primary reasons, with accumulating studies demonstrating that events including AR point mutation, rearrangement, amplification, and transcriptional upregulation of AR variants can result in the failure of AR . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.